Medifast: Steamboat and Kiai each report an 8.6% stake
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Steamboat Capital Partners, LLC and its Managing Member, Parsa Kiai, each reported beneficial ownership of 963,286 Medifast, Inc. (MED) shares, or 8.6%. The shares are owned by clients of the investment adviser, including investment funds of which an affiliate is general partner. Both reporting persons reported sole power to vote and dispose of the shares.
Clients bought shares in open-market transactions through brokers: 6,480 on October 28, 661 on November 6, 10,436 on November 18, and 100,000 on November 19, 2026. The November 19 purchase was at a weighted average price of $12.0464 per share, within a stated range of $11.855 to $12.15. The reported aggregate purchase price was approximately $10,463,681, excluding commissions. Medifast had 11,182,597 shares outstanding as of October 19, 2026.
Filing Explained
This Schedule 13D amendment reports Steamboat Capital and Parsa Kiai’s
Key Figures
Key Terms
beneficial owner regulatory
sole dispositive power regulatory
weighted average price financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.